Patent Issued for T cell activating bispecific antigen binding molecules (USPTO 12103982).

The patent issued for T cell activating bispecific antigen binding molecules by F. Hoffmann-La Roche Inc. focuses on developing antibodies that can activate immune cells to target and destroy specific cells, such as tumor cells, without harming healthy tissues. Various formats of bispecific antibodies, such as BiTEs, diabodies, DART molecules, and triomabs, are being explored for T cell engagement in immunotherapy. The patent aims to address challenges related to the efficacy, toxicity, applicability, and production of bispecific antibodies for T cell-mediated immunotherapy, highlighting the need for novel and improved formats of such molecules. [Extracted from the article]